|
|
The
Overcoming Barriers to Early Phase Trials pilot project is a
collaborative effort of the NCI, the Foundation of the National
Institutes of Health, Inc. (FNIH), and Friends of Cancer Research
(Friends),
which are in a partnership with the following pharmaceutical firms:
Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and
Novartis. The mutual goal is to enhance national capability to
test innovative therapeutic agents through supporting the
development of new models for increasing patient accrual to early
phase trials. This is one of the first of what are intended to be
many public/private partnerships designed to enhance progress in
cancer research.
The specific purpose of this
initiative is to enhance national capability to test innovative
therapeutic agents by developing a spectrum of exportable models
that NCI cancer centers and other organizations can use to
increase and sustain accrual rates of patients in the community to
these trials. Information gleaned from this pilot program also
will be used to develop CCSG guidelines for configuration of a
resource devoted to the accrual of patients to early phase trials.
Based upon these guidelines, resources could be supported by both
Cancer Center Support Grants and per patient reimbursements from
industrial sponsors.
|
